The effect of omeprazole on treatment outcomes in patients with severe traumatic brain injury and sepsis

• Autorzy: Oliynyk O.

Warianty tytułu

PL

Wpływ omeprazolu na wynik leczenia pacjentów z ciężkimi urazowymi obrażeniami mózgu i sepsą

• Języki publikacji: EN

Abstrakty

EN

Background. The interrelation between omeprazole use and the possibility of developing nosocomial pneumonia, acute kidney damage and Clostridium difficile-induced diarrhea in patients with sepsis requires further study. Material and methods. 200 patients with severe craniocerebral injury that underwent surgery for the pathology and developed sepsis in the postoperative period were examined in a blind, randomized placebo-controlled research study. The patients were divided into two groups. Patients in Group 1, as part of their therapy regimen for sepsis, received a daily dose of 0.2 mg/kg omeprazole as an intravenous infusion; patients in Group 2 received placebo instead of omeprazole, in addition to a similar therapy regimen as Group 1. Results. Among patients receiving omeprazole, the number of concomitant ventilatorassociated pneumonia cases increased by 1.32 times, the number of acute kidney damage cases by 1.33 times and the number of cases of Clostridium difficile toxin secretion with feces by 1.75 times. Conclusions. The routine use of omeprazole in the management of patients with sepsis may worsen treatment results.

PL

Wprowadzenie. Kwestia korelacji stosowania omeprazolu z możliwym rozwojem szpitalnego zapalenia płuc, ostrego uszkodzenia nerek czy biegunki wywołanej przez Clostridium difficile u pacjentów z sepsą wymaga dalszych badań. Materiał i metody. W ślepym i randomizowanym badaniu kontrolowanym placebo przebadano 200 pacjentów z poważnymi obrażeniami czaszkowo-mózgowymi, którzy w wyniku tej patologii przeszli operację, i u których w okresie pooperacyjnym rozwinęła się sepsa. Zostali oni podzieleni na dwie grupy. Grupa 1 przyjmowała omeprazol w formie wlewu dożylnego w dziennej dawce 0,2 mg/kg jako część kompleksowego leczenia sepsy; grupa 2 przyjmowała placebo zamiast omeprazolu jako dodatek do głównej terapii, podobnej do tej stosowanej w przypadku grupy 1. Wyniki. Wśród pacjentów przyjmujących omeprazol liczba przypadków towarzyszącego respiratorowego zapalenia płuc wzrosła o 1,32 raza, ostrego uszkodzenia nerek – o 1,33 raza, a wydalenia toksyn Clostridium difficile w kale – o 1,75 raza. Wnioski. Rutynowe stosowanie omeprazolu w leczeniu pacjentów z sepsą może pogorszyć wyniki terapii.

Słowa kluczowe

EN

omeprazole; treatment; human disease; patient; severe trauma; traumatic brain injury; sepsis

• Wydawca: -
• Czasopismo: Health Problems of Civilization
• Rocznik: 2021
• Tom: 15
• Numer: 2
• Opis fizyczny: p.137-141,ref.

Twórcy

autor

Oliynyk O.

• Department of Medical Rescue, Pope John Paul II State School of Higher Education, Sidorska 95/97, 21-500 Biala Podlaska, Poland

Bibliografia

• 1. Rhodes A, Evans LE, Alhazzani W. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017; 43(3): 304-377. https://doi.org/10.1007/s00134-017-4683-6
• 2. Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017; 14(12): 697-710. https://doi.org/10.1038/nrgastro.2017.117
• 3. MacLaren R, Kassel L, Kiser T. Proton pump inhibitors and histamine-2 receptor antagonists in the intensive care setting: focus on therapeutic and adverse events. Expert Opin Drug Saf. 2015; 14(2): 269-280. https://doi.org/10.1517/14740338.2015.986456
• 4. Yoshikazu K, Norihisa I, Shunji I. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil. 2018; 24(2): 182-196. https://doi.org/10.5056/jnm18001
• 5. Alhazzani W, Alenezi F, Jaeschke R. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med. 2013; 41(3): 693-705. https://doi.org/10.1097/CCM.0b013e3182758734
• 6. Strand D, Kim D, Peura D. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017; 11(1): 27-37. https://doi.org/10.5009/gnl15502
• 7. Blank M, Parkin L, Zeng J. Proton pump inhibitors and infant pneumonia/other lower respiratory tract infections: national nested case-control study. J Pediatr Gastroenterol Nutr. 2018; 67(3): https://doi.org/10.1097/MPG.0000000000001984
• 8. Spalding M, Cripps M, Minshall C. Ventilator-associated pneumonia: new definitions. Crit Care Clin. 2017; 33(2): 277-292. https://doi.org/10.1016/j.ccc.2016.12.009
• 9. Ghebremariam Y, Cooke J, Gerhart W. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. J Transl Med. 2015; 13: 249. https://doi.org/10.1186/s12967-015-0614-x
• 10. Elliott B, Androga GO, Knight DR, Riley TV. Clostridium difficile infection: evolution, phylogeny and molecular epidemiology. Infect Genet Evol. 2017; 49: 1-11. https://doi.org/10.1016/j.meegid.2016.12.018
• 11. Buendgens L, Bruensing J, Matthes M. Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile-associated diarrhea. J Crit Care. 2014; 29(4): 696.e11-696.e15. https://doi.org/10.1016/j.jcrc.2014.03.002
• 12. Azab M, Doo L, Doo D. Comparison of the hospital-acquired Clostridium difficile infection risk of using proton pump inhibitors versus histamine-2 receptor antagonists for prophylaxis and treatment of stress ulcers: a systematic review and meta-analysis. Gut Liver. 2017; 11(6): 781-788. https://doi.org/10.5009/gnl16568
• 13. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011; 34: 1269-1281. https://doi.org/10.1111/j.1365-2036.2011.04874.x
• 14. Hegarty JP, Sangster W, Harris LR, Stewart DB. Proton pump inhibitors induce changes in colonocyte gene expression that may affect Clostridium difficile infection. Surgery. 2014; 156(4): 972-978. https://doi.org/10.1016/j.surg.2014.06.074
• 15. Trifan A, Stanciu C, Girleanu I. Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis. World J Gastroenterol. 2017; 23(35): 6500-6515. https://doi.org/10.3748/wjg.v23.i35.6500
• 16. Nash DM, Przech S, Wald R, O’Reilly D. Systematic review and meta-analysis of renal replacement therapy modalities for acute kidney injury in the intensive care unit. J Crit Care. 2017; 41: 138-144. https://doi.org/10.1016/j.jcrc.2017.05.002

Identyfikatory

DOI

10.5114/hpc.2020.98946